TABLE 2.

Early effects^a of treatment with MB-III and liposomal amphotericin B on acute and established L. donovani infections in hamsters

Treatment groupb and treatment	Body wt (g) on day 0c	% Body wt gain at day 7c	Length of survival (day postinfection)	Liver wt and burdens			Other target organs
				Wt (mg)a	LDU	% Reduc- tion	Spleen wt (mg)c	No. of animals with positive:
								Spleen	Bone marrow
Treatment of acute infection on day 1 postinfection
Control (no treatment)	191 ± 32	5 ± 4	8	10,722 ± 2,051	11,237 ± 2,422		411 ± 115	5	5
MB-III at 0.2 mg/kg s.c.	161 ± 33	5 ± 4	8	8,015 ± 2,409	22 ± 40	99.8	502 ± 111	5	4
MB-III at 0.4 mg/kg s.c.	169 ± 22	5 ± 2	8	8,238 ± 1,311	1 ± 3	100	417 ± 195	5	0
MB-III at 0.8 mg/kg s.c.	197 ± 12	1 ± 2	8	8,138 ± 1,311	0 ± 0	100	351 ± 166	0	0
Amphotericin Bd at 5 mg/kg i.v.e	176 ± 43	3 ± 7	8	8,879 ± 1,896	0 ± 0	100	326 ± 145	0	1
Treatment of chronic infection on day 28 postinfection
Control (no treatment)	162 ± 35	−24 ± 14	35	11,026 ± 2,670	51,489 ± 37,220		889 ± 200	5	5
MB-III at 0.2 mg/kg s.c.	187 ± 30	−33 ± 19	35	11,412 ± 751	28,130 ± 6,476	45.4	1,195 ± 327	5	5
MB-III at 0.4 mg/kg s.c.	180 ± 23	−29 ± 14	35	11,284 ± 770	16,176 ± 11,167	68.6	1,030 ± 345	5	5
MB-III at 0.8 mg/kg s.c.	158 ± 29	−34 ± 16	35	8,752 ± 1,769	3,008 ± 2,248	94.2	692 ± 206	2	5
Amphotericin B at 5 mg/kg i.v.	163 ± 42	−22 ± 8	35	9,471 ± 2,136	331 ± 442	99.4	681 ± 290	5	5

^aEarly effects of treatment were determined by necropsy at day 7 posttreatment.

^bGroups of five animals each (males and females) received a single dose.

^cValues are means ± standard deviations.

^dLiposomal amphotericin B (AmBisome).

^ei.v., intravenously.